ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-OR25

Exploring Epitope Spreading of PLA2R and Its Clinical Relevance in Idiopathic Membranous Nephropathy (IMN) Based on Yeast Surface Display System

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Trials


  • Liu, Yanan, Peking Union Medical College Hospital, Dongcheng-qu, Beijing, China
  • Chen, Peng, Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, China
  • Hong, Junxian, Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, China
  • Qin, Yan, Peking Union Medical College Hospital, Dongcheng-qu, Beijing, China

PLA2R is the main target antigen of idiopathic membranous nephropathy (IMN). The PLA2R extracellular segment consists of Ricin, FNII and 8 CTLDs. The major epitope is located in Ricin, and CTLD1, CTLD7 and CTLD8 have also been found as epitopes. The presence of epitope spreading and its clinical significance are controversial.


A random library of PLA2R was constructed by yeast surface display technique and screened by serum from 18 patients with PLA2R-associated IMN. Serum was prospectively collected from 389 patients. A batch flow analysis was carried out with the monoclonal yeast of each epitope. The clinical value of epitope was explored. The dynamic changes of epitope profiles during follow-up were observed.


1. The first PLA2R yeast surface display system was constructed.
2. In addition to Ricin, CTLD1, CTLD7, and CTLD8, 3 new epitopes (CTLD4, CTLD5, and CTLD6) were found (Figure 1).
3. The positive rates of CTLD1 and CTLD7 were about 50%. CTLD6, CTLD8 and CTLD4 were weak epitopes with a positive rate of less than 10%. 69 (17.7%) patients had epitope limited to Ricin.
4. 24hUP increased with the number of epitopes. The relationship between epitope spreading and 24hUP in subgroup divided by anti-PLA2R titer was consistent with the whole cohort.
5. By multivariate COX regression, gender, age, baseline 24hUP, anti-PLA2R titer were adjusted. Patients with epitope number ≥4 had lower response rates than patients with only 1 epitope (HR 0.571, 95%CI 0.363-0.899, p=0.015).
6. Reversal of epitope spreading was observed in responders. Further epitope spreading was observed in non-responders.


We identified 3 new epitopes through PLA2R yeast surface display system. Epitope spreading in PLA2R was confirmed. The epitope number was correlated with 24hUP. Baseline epitope spreading had a prognostic value for remission independent of anti-PLA2R Ab titer and 24hUP. Clinical remission was accompanied with epitope reversal.


  • Clinical Revenue Support